Fatty liver represents the liver component of metabolic syndrome and may be involved in plasminogen activator inhibitor-1 (PAI-1) synthesis. We studied plasma PAI-1 levels and relationships with risk factors for metabolic syndrome, including fatty liver, in 170 patients. Liver ultrasound scan was performed on all patients, and a liver biopsy was performed on those patients with chronically elevated transaminase levels. Plasma PAI-1 levels correlated significantly (P < .05) with body mass index, degree of steatosis, insulin resistance, insulin level, waist circumference, triglycerides, and high-density lipoprotein (HDL) -cholesterol. However, only body mass index (β = .455) and HDL-cholesterol (β = .293) remained predictors of PAI-1 levels. Liver biopsy revealed a significant correlation (P < .05) between insulin resistance (r = 0.381) or insulin level (r = 0.519) and liver fibrosis. In patients presenting features of metabolic syndrome, plasma PAI-1 levels were mainly conditioned by the whole-body fat content.
Dandona P., Aljada A., Chaudhuri A., et al. Metabolic syndrome. A comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation. 2005;111:1448-1454.
3.
Alessi MC, Juhan-Vague I.PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler Thromb Vasc Biol. 2006;26:2200-2207.
Pagano G., Pacini G., Musso G., et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology. 2002;35:367-372.
6.
Angelico F., Del Ben M., Conti R., et al. Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 2005;90:1578-1582.
7.
Marchesini G. , Bugianesi E., Forlani G., et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003 ;37:917-923.
8.
Marchesini G. , Brizi M., Bianchi G., et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001;50:1844-1850.
9.
Dixon JB, Bhathal PS, Hughes NR, et al. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology. 2004 ;39:1647-1654.
10.
Fassio E., Alvarez E., Dominguez N., et al. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology. 2004;40:820-826.
Adams LA, Sanderson S., Lindor KD, et al. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol. 2005;42:132-138.
Festa A., D'Agostino R., Tracy RP, et al. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes. 2002;51:1131-1137.
15.
Mavri A., Alessi MC, Juhan-Vague I.Hypofibrinolysis in the insulin syndrome: implication in cardiovascular disease . J Intern Med. 2004;255:448-456.
16.
Juhan-Vague I. , Alessi MC, Mavri A., et al. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost. 2003;1: 1575-1579.
17.
Solano MP, Perry AC, Wang X., Ross R., Goldberg RBInsulin resistance but not visceral adipose tissue is associated with plasminogen activator inhibitor type 1 levels in overweight and obese premenopausal African-American women. Int J Obes Relat Metab Disord. 2003 ;27:82-87.
18.
Meigs JB, Mittleman MA, Nathan DM, et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham offspring study. JAMA. 2000; 283:221-228.
19.
Cigolini M., Targher G., Agostino G., et al. Liver steatosis and its relation to plasma haemostatic factors in apparently healthy men. Role of the metabolic syndrome. Thromb Haemost. 1996;76:69-73.
20.
Alessi MC, Bastelica D., Mavri A., et al. Plasma PAI-1 levels are more strongly related to liver steatosis than to adipose tissue accumulation. Arterioscler Thromb Vasc Biol. 2003;23:1262-1268.
21.
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP).Expert Panel of Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
22.
Rosito GA, D'Agostino RB, Massaro J., et al. Association between obesity and prothrombotic state: the Framingham offspring study. Thromb Haemost. 2004;91:683-689.
23.
Lijnen HR, Alessi MC, Van Hoef B., et al. On the role of plasminogen activator inhibitor-1 in adipose tissue development and insulin resistance in mice. J Thromb Haemost. 2005;3:1174-1179.
24.
Ma LJ, Mao SL, Taylor KL, et al. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes. 2004;53:336-346.
25.
Hoekstra T. , Geleijnse JM, Schouten EG, et al. Plasminogen activator inhibitor-type-1: its plasma determinants and relation with cardiovascular risk. Thromb Haemost. 2004;91:861-872.
26.
Bergheim I. , Guo L., Davis MA, et al. Metformin prevents alcohol-induced liver injury in the mouse: critical role of plasminogen activator inhibitor-1 . Gastroenterology. 2006; 130:2099-2112.
27.
Seppälä-Lindroos A., Vehkavaara S., Häkkinen AM, et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab. 2002;87:3023-3028.
28.
Lonardo A., Lombardini S., Scaglioni F., et al. Hepatic steatosis and insulin resistance: does etiology make a difference? J Hepatol. 2006;44:190-196.
29.
Promrat K., Lutchman G., Uwaifo GI, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis . Hepatology. 2004;39:188-196.
30.
Duseja A., Murlidharan R., Bhansali A., et al. Assessment of insulin resistance and effect of metformin in nonalcoholic steatohepatitis - a preliminary report. Indian J Gastroenterol. 2004;23:12-15.
31.
Skurk T., Hauner H.Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1. Int J Obes Relat Metab Disord. 2004;28: 1357-1364.
32.
Palomba S., Orio F. Jr, Falbo A., et al. Plasminogen activator inhibitor 1 and miscarriage after metformin treatment and laparoscopic ovarian drilling in patients with polycystic ovary syndrome. Fertil Steril. 2005;84:761-765.
33.
Bugianesi E. , Manzini P., D'Antico S., et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver . Hepatology. 2004;39:179-187.
